Treatment Horizons

LifeGuide HIV drug development faces challenges by Jeannie Wraight and Mariel Selbovitz, MPH Triple and now quad drugs like Gilead’s Atripla and their new compound known...

LifeGuide Treatment Horizons The Road Ahead New candidates hold promise for ARV therapy & therapeutic vaccines by Mariel Selbovitz, MPH The 54th Interscience Conference on Antimicrobial Agents and Chemotherapy...

At the 16th European AIDS Conference in Milan, Italy, on October 25, 2017, Janssen Pharmaceutica, NV announced the results of its Phase 3 AMBER...

A newly completed study of 358 serodiscordant gay couples has not found a single case of HIV transmission in 16,889 acts of condomless anal...

On November 21, 2017, the U.S. Food and Drug Administration (FDA) approved the first-ever two-drug once-daily single-pill regimen for the maintenance treatment of adults...

Sun Blocked A new study examines non-melanoma skin cancers & HIV by Chael Needle In the pre-HAART era, an AIDS diagnosis or even an HIV-positive diagnosis illuminated...

NAPWA helps to promote immune-based therapies by Chael Needle At the International AIDS Conference last June, the AIDS Institute and the National Association of People with AIDS...

Natasha Travis, MD, helps shape the HIV learning curve for physicians and patients by Chael Needle Awarded a 2012 Minority Clinical Fellowship by the HIV Medicine...

A newly approved anti-diarrheal agent seeks to counter side effects of HAART by Chael Needle Recently, the FDA approved Fulyzaq (crofelemer) 125 mg delayed-release tablets for...

Last month, the Member States of the United Nations adopted the “Political Declaration on HIV and AIDS: On the Fast-Track to Accelerate the Fight...